Homepage Top Section 2

In preclinical and Phase I studies in healthy participants, PORT-77 demonstrated a substantial reduction of plasma protoporphyrin IX (PPIX) through rapid ABCG2 inhibition. This outcome has the potential

The treatment, designed to be administered either as an injectable or an oral medication, utilises the regulation of the brain’s nitric oxide (NO) levels to influence neurological function.

The centre will focus on the early detection of diseases and design treatments for improved patient outcomes using precision medicine. Metabolomics, the study of small molecules or metabolites,

EVO756 is a highly selective small molecule antagonist targeting mas-related G-protein coupled receptor X2 (MRGPRX2), a receptor implicated in various inflammatory conditions. This partnership builds on a previous

Cabotegravir is indicated for use in high-risk adults and adolescents aged a minimum of 12 years weighing at least 35 kg. It is claimed to be the first

Under the agreement, Synaffix will be eligible for an upfront payment, milestone payments along with tiered royalties on net sales of resulting products. The company will also produce

The provisional approval comes with a duration of two years. It is based on the data from Phase II studies that enrolled highly sensitised patients who received imlifidase

As per the terms of the deal, OEP will receive exclusive rights from OncoVent to commercialise oregovomab in Taiwan. The licence will also cover related regulatory applications and

ENHERTU, which is a HER2 directed ADC, features a HER2 monoclonal antibody attached to a topoisomerase I inhibitor payload through a stable tetrapeptide-based cleavable linker. The approval of